Advertisement

Topics

AstraZeneca strikes mRNA-based partnership in respiratory disease

05:45 EDT 22 Aug 2017 | Pharmafile

AstraZeneca and MedImmune, the company’s biologics research arm, have forged a five year research partnership with mRNA-based pulmonary disease specialist Ethris to leverage the latter’s proprietary SNIM RNA technology in the development of stabilised non-immunogenic modified RNA therapies for respiratory diseases.

read more

Original Article: AstraZeneca strikes mRNA-based partnership in respiratory disease

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca strikes mRNA-based partnership in respiratory disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...